0001181431-13-053304.txt : 20131009 0001181431-13-053304.hdr.sgml : 20131009 20131009160136 ACCESSION NUMBER: 0001181431-13-053304 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20131009 FILED AS OF DATE: 20131009 DATE AS OF CHANGE: 20131009 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: MACROGENICS INC CENTRAL INDEX KEY: 0001125345 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE BUSINESS ADDRESS: STREET 1: 9640 MEDICAL CENTER DRIVE CITY: Rockville STATE: MD ZIP: 20850 BUSINESS PHONE: 301-251-5172 MAIL ADDRESS: STREET 1: 9640 MEDICAL CENTER DRIVE CITY: ROCKVILLE STATE: MD ZIP: 20850 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Nadav Eran CENTRAL INDEX KEY: 0001587852 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36112 FILM NUMBER: 131143476 MAIL ADDRESS: STREET 1: 301 COMMERCE STREET STREET 2: SUITE 3300 CITY: FORT WORTH STATE: TX ZIP: 76102 3 1 rrd392555.xml FORM 3 X0206 3 2013-10-09 0 0001125345 MACROGENICS INC MGNX 0001587852 Nadav Eran C/O TPG GLOBAL, LLC 301 COMMERCE STREET, SUITE 3300 FORT WORTH TX 76102 1 0 0 0 No securities beneficially owned 0 D Dr. Eran Nadav is a TPG Principal. TPG is affiliated with TPG Biotechnology Partners, L.P. and TPG Ventures, L.P. (collectively, the "TPG Funds"), which collectively hold shares of Series B Preferred Stock, Series C Preferred Stock and Series D-2 Preferred Stock (collectively, the "TPG Preferred Stock") of MacroGenics, Inc. ("the Issuer") and warrants to purchase shares of Series D-2 Preferred Stock of the Issuer (the "TPG Warrants"), which are convertible or exercisable into an aggregate of 2,209,934 shares (the "TPG Shares" and, together with the TPG Preferred Stock and the TPG Warrants, the "TPG Securities") of Common Stock, par value $0.01 per share, of the Issuer. Dr. Nadav disclaims beneficial ownership of all of the TPG Securities that are or may be beneficially owned by the TPG Funds or any of their affiliates. Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that Dr. Nadav is, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owner of any equity securities of the Issuer for purposes of Section 16 of the Exchange Act or otherwise. Ronald Cami is signing on behalf of Dr. Nadav pursuant to the authorization and designation letter dated September 24, 2013, which is filed as an exhibit to this Form 3. /s/ Ronald Cami on behalf of Eran Nadav 2013-10-09 EX-24. 2 rrd353160_399986.htm AUTHORIZATION LETTER rrd353160_399986.html 
TPG

                               September 24, 2013


Securities and Exchange Commission
100 F Street, NE
Washington, DC 20549

        This letter confirms that Ronald Cami, John E. Viola and David Reintjes
are authorized and designated to sign all securities related filings with the
Securities and Exchange Commission, including Form ID Acknowledgements, on my
behalf. This authorization and designation shall be valid for three years from
the date of this letter.

                                        Very truly yours,

                                        /s/ Dr. Eran Nadav
                                        ---------------------------------------
                                        Dr. Eran Nadav